
Inventia
Founded Year
2012Stage
Acquired | AcquiredTotal Raised
$850KAbout Inventia
Inventia is a provider of Digital Onboarding, Video Biometric Recognition and Video Collaboration services using software technology Phygital 4X. Inventia combines Artificial Intelligence, Video Engagement, Remote Collaboration, Identity Recognition, Biometrics and Digital Signature, creating a 'Phygital' (physical + digital) experience which helps companies increase online conversion rates, enabling the sale of products and services that today present limitations of a regulatory nature or of elevated complexity.On February 11th, 2020, Inventia was acquired by CRIF, terms of the agreement were not disclosed.
Inventia Headquarter Location
Via Antonio Fontanesi, 4
Milan, 20146,
Italy
+39-0236-696490
Research containing Inventia
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Inventia in 1 CB Insights research brief, most recently on Feb 14, 2020.
Expert Collections containing Inventia
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Inventia is included in 1 Expert Collection, including Artificial Intelligence.
Artificial Intelligence
8,717 items
This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.
Inventia Patents
Inventia has filed 8 patents.
The 3 most popular patent topics include:
- Authentication methods
- Computer memory
- Diabetes
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
4/3/2018 | 9/21/2021 | Authentication methods, Password authentication, Cryptographic protocols, Computer network security, Identity management | Grant |
Application Date | 4/3/2018 |
---|---|
Grant Date | 9/21/2021 |
Title | |
Related Topics | Authentication methods, Password authentication, Cryptographic protocols, Computer network security, Identity management |
Status | Grant |
Latest Inventia News
Sep 23, 2021
September 23, 2021 PARIS, FRANCE: Inventiva, a clinical-stage biopharmaceutical company, has completed sales of 2.083 million American Depositary Shares (ADS) pursuant to the company’s ATM program established on August 2, 2021, through Jefferies LLC. Each American Depositary Shares (ADS) represents one ordinary share of the company. In the ATM sales, an aggregate of 2,083,334 new American Depositary Shares (ADS) and the same number of underlying new ordinary shares have been issued to existing and new specialized institutional investors through a capital increase at a price of $14.40 per new ADS, without a discount to the volume weighted average price of the company’s ADS over the last trading day and representing a discount of 3% to the volume weighted average price of the company’s ordinary shares on the regulated market of Euronext in Paris over the last trading day. The new shares will represent 5.1% of the share capital of the company upon completion of the transaction. It is anticipated that the settlement and delivery of the new shares will take place on September 27, 2021. They will be admitted to trading on Euronext and the issued ADSs will trade on Nasdaq. Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need. The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly‑owned research and development facility. Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris and on the Nasdaq Global Market in the United States. www.inventivapharma.com
When was Inventia founded?
Inventia was founded in 2012.
Where is Inventia's headquarters?
Inventia's headquarters is located at Via Antonio Fontanesi, 4, Milan.
What is Inventia's latest funding round?
Inventia's latest funding round is Acquired.
How much did Inventia raise?
Inventia raised a total of $850K.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.